A Phase 3 interventional study of VEC-162 20 mg and Placebo in Primary Insomnia, sponsored by Vanda Pharmaceuticals. Completed at 35 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 146 open to participants now, 183 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.
Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 102nd largest by enrollment of the 855 interventional ones that give a count, is one of 34 that started in 2007, is one of 68 in phase 3, and was the 98th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →146 of the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:
Florida State University · Sites in United States
Ages 6–13 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
Eight Sleep Inc. · Sites in United States
Ages 45+ · Healthy volunteers
Proactive Life Inc · Sites in United States
Ages 55+
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
903 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 103 · Phase 3 77 · Phase 4 78
First in 1997; this study’s year is marked. 34 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 322 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 855 interventional studies, 72 across the 48 observational. Of the 660 that completed or were terminated, 243 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 903 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
78 of the studies in Sleep Initiation and Maintenance Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 78 to your calendar (.ics) → With an account.
Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
Drug: VEC-162 20 mg
VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
Drug: VEC-162 50 mg
Placebo capsules PO daily five weeks
Drug: Placebo
20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
Placebo capsules, PO daily for five weeks
50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
Average Change From Baseline - Latency to Persistent Sleep (LPS)
Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point at which 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline and the average of nights 1 and 8.
Time frame: Baseline, Night 1, and Night 8 measurement
Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)
Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 1 and 8. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 1 and 8.
Time frame: Baseline, Night 1, and Night 8 measurements for WASO and TST
| Milestone | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Started | 109 | 109 | 104 |
| Completed | 101 | 98 | 95 |
| Not completed | 8 | 11 | 9 |
| Withdrew: Protocol violation | 2 | 3 | 3 |
| Withdrew: Adverse event | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 4 | 3 |
| Withdrew: Other | 1 | 1 | 1 |
Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point at which 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline and the average of nights 1 and 8.
| minutes | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Average Change From Baseline - Latency to Persistent Sleep (LPS) | 45.0 ± 2.965 | 46.4 ± 2.954 | 28.3 ± 3.020 |
Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 1 and 8. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 1 and 8.
| minutes | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Avg WASO Change from Baseline | 12.2 ± 4.349 | 14.1 ± 4.329 | 11.7 ± 4.569 |
| Avg TST Change from Baseline | 51.4 ± 4.794 | 52.0 ± 4.775 | 39.9 ± 4.882 |
Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline, and the average of nights 22 and 29.
| minutes | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Average Change From Baseline - Latency to Persistent Sleep (LPS) | 49.4 ± 3.309 | 45.1 ± 3.292 | 33.9 ± 3.338 |
Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 22 and 29. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 22 and 29.
| minutes | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Avg WASO Change from Baseline | 17.7 ± 4.139 | 10.2 ± 4.184 | 20.3 ± 4.381 |
| Avg TST Change from Baseline | 60.3 ± 4.821 | 48.6 ± 4.802 | 47.4 ± 4.882 |
Collected over Night 1 to Day 37 (EOS). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VEC-162 20 mg | — | 1/109 (0.9%) | 15/109 (13.8%) |
| VEC-162 50 mg | — | 0/109 (0%) | 13/109 (11.9%) |
| Placebo | — | 1/104 (1%) | 11/109 (10.1%) |
| Event | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| Hypertensive EmergencyVascular disorders | 0/109 | 0/109 | 1/104 |
| Blood Pressure IncreasedInvestigations | 1/109 | 0/109 | 0/104 |
| Event | VEC-162 20 mg | VEC-162 50 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 11/109 | 4/109 | 5/109 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 0/109 | 5/109 | 2/109 |
| NasopharyngitisInfections and infestations | 3/109 | 4/109 | 4/109 |
| Urinary Tract InfectionInfections and infestations | 4/109 | 2/109 | 1/109 |
| Age, Continuous(years) | VEC-162 20 mg | VEC-162 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 42.9 ± 10.6 | 40.7 ± 10.4 | 41.7 ± 11.8 | 41.8 ± 10.9 |
| Age, Categorical(Participants) | VEC-162 20 mg | VEC-162 50 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 109 | 109 | 104 | 322 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | VEC-162 20 mg | VEC-162 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 66 | 63 | 68 | 197 |
| Male | 43 | 46 | 36 | 125 |
The record gives a start of Nov 2007, a primary completion of Feb 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 8 months after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Initiation and Maintenance Disorders →